INS and type 2 diabetes mellitus: Our group recently carried out a proof-of-concept study by exploiting alpha-lipoic acid (α-LA), an insulin-mimetic already used as a nutraceutical approach to the treatment of T2DM and hepatic steatosis, in an in vitro model of AIP.